Ozempic vs Mounjaro
Ozempic and Mounjaro are the FDA-approved type-2 diabetes brands of the GLP-1 class. Ozempic is semaglutide; Mounjaro is tirzepatide. Mounjaro produces larger average A1C reduction and larger weight loss at tolerated dose; Ozempic carries the longer cardiovascular outcome track record. The right molecule is a provider-reviewed match.
Choose Ozempic when the cardiovascular outcome data is the priority for the patient's risk profile or when access and tolerance favor semaglutide.
Choose Mounjaro when the priority endpoint is larger A1C reduction or larger weight effect at maximum tolerated dose and candidacy supports it.
Educational. Final pathway selection is provider-reviewed via synchronous video consultation against your biomarkers, history, and goals.
Frequently asked
Are these the same as the weight-loss brands?
Same molecules. Ozempic and Wegovy are both semaglutide. Mounjaro and Zepbound are both tirzepatide. The FDA-approved indications and dosing schedules differ.
Can I use a T2DM brand for weight loss?
Off-label use is a provider-reviewed decision and depends on candidacy, insurance, and access. The weight-management brands (Wegovy, Zepbound) are the on-label option for weight indication.
Take the optimization assessment.
The adaptive assessment maps your symptoms, history, and goals to candidate pathways — and routes you into provider review.
Begin assessment